<DOC>
	<DOCNO>NCT00931255</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy conversion tacrolimus sirolimus early kidney transplantation patient delay graft function ( DGF ) slow graft function ( SGF ) improve graft function delay chronic allograft nephropathy . The investigator hypothesize conversion tacrolimus sirolimus renal transplant recipient DGF/SGF early month surgery improve graft function decrease progression graft fibrosis .</brief_summary>
	<brief_title>Tacrolimus Sirolimus Conversion Delayed Graft Function</brief_title>
	<detailed_description>Eligible study subject randomize two group 8-18 week surgery . One group maintain tacrolimus accord standard care center . In second group tacrolimus convert sirolimus , one week overlap sirolimus therapy tacrolimus taper . All decease donor kidney transplant recipient transplant center experience DGF/SGF eligible inclusion study , meet inclusion/exclusion criterion detail later . Data collect patient demographic , duration dialysis , history diabetes chronic hepatitis C , previous transplantation , PRA , donor source , warm cold ischemia time , donor demographic comorbidity diabetes hypertension , serum creatinine time organ removal , early graft function , number dialysis treatment transplantation , induction agent immunosuppressive regimen include dose level drug 3 , 6 , 9 , 12 , 18 , 24 month . Similar data regard use ACE inhibitors/ARBs , erythropoietic agent , number anti-hypertensives lipid lower agent collect . In addition , follow test procedure obtain study . 1 . GFR measurement cold iothalamate method one year transplantation . 2 . Evaluation routine surveillance graft biopsies chronic change 3 12 month posttransplant morphometric analysis . 3 . Spot urine protein , albumin , creatinine measurement 3 12 month . 4 . Estimate GFR 3 , 12 month use MDRD , CG , Nankivell formulas 5 . Examine surveillance indicated biopsy acute rejection BK nephropathy . 6 . Fasting lipid profile 3 12 month patient , 24 month least 2 year follow . 7 . Office blood pressure measurements 3 12 month patient , 24 month least 2 year follow . 8 . Measurement CRP , IL-6 , MCP 3 12 month . The safety measure include : Incidence leukopenia ( WBC &lt; 3000 ) thrombocytopenia ( PLT &lt; 100,000 ) ; hemoglobin level 12 month ; proteinuria 12 month ; incidence oral aphthous ulcer ; incidence new onset diabetes , incidence CMV infection rate drug withdrawal due side effect .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Age = &gt; 18 . 2 . Recipient decease donor kidney transplant . 3 . Delayed graft function , define need dialysis first week surgery slow graft function , define creatinine &gt; =3.0 postop day 5 without require dialysis 4 . Stable serum creatinine 2 week prior enrollment . 5 . Able give inform consent . 6 . Compliant medical regimen clinic visit . 1 . Episode acute rejection within 4 week prior enrollment . 2 . Calculated GFR &lt; 30 ml/min . 3 . Interstitial fibrosis &amp; tubular atrophy transplant biopsy high grade II ( Banff '' 05 update ) . 4 . Proteinuria &gt; 500 mg/24 h spot urine protein/creatinine &gt; 0.5 . 5 . Total fast cholesterol level &gt; 300 mg/dl triglyceride &gt; 500 mg/dl despite optimal lipid lower therapy . 6 . Recipient pancreas liver allograft . 7 . Leukopenia ( WBC &lt; 3000 mm3 ) within 2 week prior enrollment . 8 . Leukopenia ( WBC &lt; 2000 mm3 ) within 4 week prior enrollment . 9 . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) within 2 week prior enrollment . 10 . Unwilling comply study protocol . 11 . Enrollment another drug trial precludes use sirolimus . 12 . Diagnosis malignancy within 2 year prior enrollment , except adequately treat nonmelanoma skin cancer . 13 . For woman , pregnancy . 14 . Allergy iodine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>sirolimus</keyword>
	<keyword>delay graft function</keyword>
	<keyword>Graft survival</keyword>
	<keyword>Acute rejection</keyword>
	<keyword>Chronic allograft nephropathy</keyword>
</DOC>